Brief Summary
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Protocol Interventions
Drug: Ziftomenib, Drug: Fludarabine, Drug: Idarubicin, Drug: Cytarabine, Drug: Gilteritinib, Biological: Granulocyte colony-stimulating factor